Critically for the clinical context, recent studies have indicated better prognosis among high-grade serous ovarian cancers with high CD8+ T cell infiltrates and CXCL9 levels, supporting the potential clinical significance of our approach [40, 48]. The gene discussed is CXCL9; the disease is ovarian serous adenocarcinoma.